He Z X, Cwajg E, Hwang W, Hartley C J, Funk E, Michael L H, Verani M S
Section of Cardiology, Baylor College of Medicine/Methodist Hospital, Houston, Tex, USA.
Circulation. 2000 Jul 25;102(4):438-44. doi: 10.1161/01.cir.102.4.438.
We investigated the hemodynamic and coronary vasodilatory effects of CGS-21680, a potent selective adenosine A(2A) agonist, as well as its potential use as a new stress modality in combination with perfusion scintigraphy.
A stenosis of the left anterior descending coronary artery (LAD) was produced in dogs to reduce the reactive hyperemic response to <20%. Adenosine and CGS-21680 were then separately infused to maximize left circumflex coronary artery (LCx) flow velocity. (201)Tl (0.5 mCi) and (99m)Tc-sestamibi (5 mCi) were injected at the maximal dose of CGS-21680. Heart rate decreased with adenosine but increased during CGS-21680 infusion (P<0.005). The decrease in systolic blood pressure was more prominent with adenosine than with CGS-21680 (P<0.005). In the control LCx zone, maximal myocardial blood flow (MBF) (measured by radioactive microspheres) increased 3.1-fold during adenosine infusion (P<0.005) and 3.8-fold during CGS-21680 infusion (P<0.005). In the stenotic LAD zone, MBF did not change significantly. During adenosine and CGS-21680 infusion, stenosis/control zone MBF ratios were comparable (0.32+/-0.11 versus 0.27+/-0.10, P=NS), and transmural (201)Tl and (99m)Tc-sestamibi count-activity ratios (0.48+/-0.11 and 0.51+/-0.09, respectively) were also comparable (P=NS). Myocardial scintigraphy uncovered perfusion defects in all dogs.
CGS-21680 elicits coronary vasodilation comparable to that of adenosine and produces profound heterogeneity of MBF and of (201)Tl and (99m)Tc-sestamibi myocardial uptake, rendering it a promising agent for pharmacological myocardial perfusion imaging.
我们研究了强效选择性腺苷A(2A)激动剂CGS-21680的血流动力学和冠状动脉舒张作用,以及其作为一种新的应激模式与灌注闪烁扫描联合应用的潜在用途。
在犬身上制造左前降支冠状动脉(LAD)狭窄,使反应性充血反应降低至<20%。然后分别输注腺苷和CGS-21680,以使左旋冠状动脉(LCx)流速最大化。在CGS-21680最大剂量时注射(201)Tl(0.5 mCi)和(99m)Tc-司他米比(5 mCi)。腺苷输注时心率下降,但CGS-21680输注期间心率增加(P<0.005)。腺苷引起的收缩压下降比CGS-21680更显著(P<0.005)。在对照的LCx区域,腺苷输注期间最大心肌血流量(MBF)(通过放射性微球测量)增加3.1倍(P<0.005),CGS-21680输注期间增加3.8倍(P<0.005)。在狭窄的LAD区域,MBF无显著变化。腺苷和CGS-21680输注期间狭窄/对照区域MBF比值相当(0.32±0.11对0.27±0.10,P=无显著性差异),跨壁(201)Tl和(99m)Tc-司他米比计数-活性比值(分别为0.48±0.11和0.51±0.09)也相当(P=无显著性差异)。心肌闪烁扫描发现所有犬均有灌注缺损。
CGS-21680引起的冠状动脉舒张与腺苷相当,并产生MBF以及(201)Tl和(99m)Tc-司他米比心肌摄取的显著异质性,使其成为药物心肌灌注成像的一种有前景的药物。